- increased circulating calcium level / IMPC
- decreased body length / IMPC
- increased circulating HDL cholesterol level / IMPC
- increased circulating glycerol level / IMPC
- increased circulating cholesterol level / IMPC
- increased circulating amylase level / IMPC
- decreased circulating fructosamine level / IMPC
- decreased bone mineral content / IMPC
C57BL/6N-Zmym4em1(IMPC)Wtsi/WtsiPh
Status | Available to order |
EMMA ID | EM:14449 |
International strain name | C57BL/6N-Zmym4em1(IMPC)Wtsi/WtsiPh |
Alternative name | |
Strain type | Endonuclease-mediated |
Allele/Transgene symbol | Zmym4em1(IMPC)Wtsi |
Gene/Transgene symbol | Zmym4 |
Information from provider
Provider | Wellcome Trust Sanger Institute |
Provider affiliation | Wellcome Trust Sanger Institute |
Genetic information | This mouse line originates from CRISPR zygote microinjection. For further details see the project page at the IMPC portal. |
Phenotypic information | Potential phenotyping data in the IMPC portal |
References | None available |
Information from EMMA
Archiving centre | Institute of Molecular Genetics, Prague, Czech Republic |
Disease and phenotype information
IMPC phenotypes (allele matching)
IMPC phenotypes (gene matching)
- increased circulating HDL cholesterol level / IMPC
- increased circulating calcium level / IMPC
- increased circulating glycerol level / IMPC
- decreased circulating fructosamine level / IMPC
- increased circulating cholesterol level / IMPC
- decreased body length / IMPC
- decreased bone mineral content / IMPC
- increased circulating amylase level / IMPC
Information on how we integrate external resources can be found here
INFRAFRONTIER® and European Mouse Mutant Archive - EMMA® are registered trademarks at the European Union Intellectual Property Office (EUIPO).